标准EVAR与开窗/分支EVAR联合髂分支装置治疗复杂主髂动脉瘤的预后比较:pELVIS登记研究
基于pELVIS登记数据库,比较髂分支装置(IBD)联合标准EVAR(629例)与联合开窗/分支EVAR(f/bEVAR,40例)治疗复杂主髂动脉瘤的预后。两组技术成功率、30天死亡率和12个月生存率无显著差异,但f/bEVAR+IBD组12个月免于动脉瘤相关再干预率显著更低(86.4% vs 93%,p=0.046)。
要点
- f/bEVAR+IBD与标准EVAR+IBD的早期及1年结果总体相当。
- f/bEVAR+IBD组12个月免于动脉瘤相关再干预率显著低于标准EVAR+IBD组。
- 复杂主髂动脉疾病使用f/bEVAR+IBD需关注再干预风险。
核心结论
- f/bEVAR+IBD治疗复杂主髂动脉疾病可获得与标准EVAR+IBD相当的早期和1年结果,但f/bEVAR组再干预率略高。
研究设计与样本
- pELVIS登记数据库回顾性分析,纳入8个欧洲中心669例患者,其中629例接受标准EVAR+IBD,40例接受f/bEVAR+IBD。
- 标准EVAR+IBD组平均年龄72.1±8.8岁,597例男性;f/bEVAR+IBD组平均年龄71.1±8.0岁,40例男性。
- f/bEVAR+IBD组平均主动脉瘤直径46.4±13.3 mm,标准EVAR+IBD组45.0±15.5 mm。
- 两组基线临床特征和动脉瘤形态相似。
主要发现
- 技术成功率f/bEVAR+IBD组100%,标准EVAR+IBD组99%(p=0.85)。
- 30天死亡率分别为0%和0.5%(p=0.66),30天再干预率分别为7.5%和4.1%(p=0.31)。
- f/bEVAR+IBD组平均随访32.1±21.3个月(n=30),标准EVAR+IBD组35.5±26.8个月(n=571;p=0.41)。
- 12个月生存率标准EVAR+IBD组93.4%(95%CI 93.2%-93.6%),f/bEVAR+IBD组93.6%(95%CI 93.3%-93.9%)(p=0.93)。
- 12个月免于动脉瘤相关再干预率标准EVAR+IBD组93%(95%CI 92.7%-93.3%),f/bEVAR+IBD组86.4%(95%CI 85.9%-86.9%)(p=0.046)。
关键数值与推荐
- f/bEVAR+IBD组12个月无闭塞或III型内漏发生;标准EVAR+IBD组12个月免于闭塞率97%(95%CI 96.8%-97.2%),免于III型内漏率98.5%(95%CI 98.4%-98.6%)。
临床怎么用
- 对于复杂主髂动脉疾病,f/bEVAR+IBD可作为可选方案,但需告知患者再干预风险可能较高。
- 术后随访应关注f/bEVAR+IBD患者的再干预需求。
局限性
- f/bEVAR+IBD组样本量较小(40例),随访数据仅30例。
- 回顾性登记研究设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To compare the outcomes of iliac branch devices (IBD) used in combination with standard endovascular aneurysm repair (EVAR) vs with fenestrated/branched EVAR (f/bEVAR) to treat complex aortoiliac aneurysms. Materials and Methods: The pELVIS Registry database containing the outcomes of IBD use at 8 European centers was interrogated to identify all IBD procedures that were combined with either standard EVAR or f/bEVAR. Among 669 patients extracted from the database, 629 (mean age 72.1±8.8 years; 597 men) had received an IBD combined with standard EVAR vs 40 (mean age 71.1±8.0 years; 40 men) who underwent f/bEVAR with an IBD. The mean aortic aneurysm diameters were 46.4±13.3 mm in the f/bEVAR patients vs 45.0±15.5 mm in the standard EVAR cases. The groups were similar in terms of baseline clinical characteristics and aneurysm morphology. The Kaplan-Meier method was used to compare patient survival, IBD occlusion, type III endoleak, and aneurysm-related reinterventions in follow-up. The estimates are presented with the 95% confidence interval (CI). Results: Technical success was 100% in the f/bEVAR+IBD group and 99% in the EVAR+IBD group (p=0.85). The 30-day mortality was 0% vs 0.5%, respectively (p=0.66), while the 30-day reintervention rates were 7.5% vs 4.1% (p=0.31). The mean follow-up was 32.1±21.3 months for f/bEVAR+IBD patients (n=30) and 35.5±26.8 months for EVAR+IBD patients (n=571; p=0.41). The 12-month survival estimates were 93.4% (95% CI 93.2% to 93.6%) in the EVAR+IBD group vs 93.6% (95% CI 93.3% to 93.9%) for the f/bEVAR+IBD group (p=0.93). There were no occlusions or type III endoleaks in the f/bEVAR+IBD group at 12 months, while the estimates for freedom from occlusion and from type III endoleak in the EVAR+IBD group were 97% (95% CI 96.8% to 97.2%) and 98.5% (95% CI 98.4% to 98.6%), respectively. The 12-month estimates for freedom for aneurysm-related reintervention were 93% (95% CI 92.7% to 93.3%) in the EVAR+IBD group vs 86.4% (95% CI 85.9% to 86.9%) in the f/bEVAR+IBD patients (p=0.046). Conclusion: Treatment of complex aortoiliac disease with f/bEVAR+IBD can achieve equally good early and 1-year outcomes compared to treatment with IBDs and standard bifurcated stent-grafts, except for a somewhat higher reintervention rate in f/bEVAR patients.
引用
- Spanos K, Kölbel T, Scheerbaum M, et al. Iliac Branch Devices With Standard vs Fenestrated/Branched Stent-Grafts: Does Aneurysm Complexity Produce Worse Outcomes? Insights From the pELVIS Registry. J Endovasc Ther. 2020. PMID: 32748727. doi:10.1177/1526602820944611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。